【摘要】：目的觀察華蟾素注射液聯(lián)合多西他賽及卡鉑方案治療晚期非小細(xì)胞肺癌(NSCLC)的臨床療效及安全性。方法將98例晚期NSCLC患者分為觀察組(49例)和對(duì)照組(49例),所有患者均接受多西他賽+卡鉑方案(第1天多西他賽60mg/m~2靜脈輸液,第2天卡鉑注射液300mg/m~2靜脈輸液全身化療,3周為1個(gè)療程,共4~6個(gè)療程,觀察組化療同時(shí)在第1~14天聯(lián)合使用華蟾素注射液20mL/d;評(píng)價(jià)患者治療后的療效、生存質(zhì)量及不良反應(yīng)。結(jié)果經(jīng)4個(gè)療程治療后,觀察組總緩解率(ORR)34.69%,疾病控制率(DCR)69.39%,對(duì)照組ORR 20.41%,DCR 34.69%,觀察組ORR及DCR顯著高于對(duì)照組(P0.05);觀察組無(wú)進(jìn)展生存期(PFS)為(6.5±1.2)個(gè)月,對(duì)照組為(2.9±1.1)個(gè)月,兩組比較差異有統(tǒng)計(jì)學(xué)意義(P0.05);兩組患者主要不良反應(yīng)均較輕,患者均可耐受。結(jié)論晚期NSCLC患者應(yīng)用華蟾素聯(lián)合多西他賽卡鉑化療后能夠控制病情進(jìn)展,延長(zhǎng)PFS,改善患者生活質(zhì)量,且不良反應(yīng)小,耐受性良好。
[Abstract]:Objective to observe the clinical efficacy and safety of cinobufagin injection combined with docetaxel and carboplatinum regimen in the treatment of advanced non-small cell lung cancer (NSCLC). Methods 98 patients with advanced NSCLC were divided into observation group (49 cases) and control group (49 cases). All patients received docetaxel 60mg/m~2 intravenous infusion on the first day. On the second day, carboplatin injection 300mg/m~2 intravenous infusion systemic chemotherapy, 3 weeks as a course of treatment, a total of 4 courses of treatment, the observation group chemotherapy at the same time on the 1st to 14th day combined use of cinobufagin injection 20 mL d; To evaluate the curative effect, quality of life and adverse reactions after treatment. Results after four courses of treatment, the total remission rate of (ORR) was 34.69%, the disease control rate of (DCR) was 6939%, the ORR of control group was 20.41%, and the ORR of control group was 34.69%. The ORR and DCR of observation group were significantly higher than those of control group (P 0.05). The non-progressive survival time of the observation group was (6.5 鹵1.2) months, and that of the control group was (2.9 鹵1.1) months, there was significant difference between the two groups (P 0.05). The main adverse reactions of the two groups were mild and tolerable. Conclusion cinobufagin combined with docetaxel chemotherapy in patients with advanced NSCLC can control the progress of the disease and prolong PFS, to improve the quality of life of patients with low adverse reactions and good tolerance.
【作者單位】： 山東省東營(yíng)市東營(yíng)區(qū)人民醫(yī)院藥劑科;山東省東營(yíng)市東營(yíng)區(qū)新區(qū)醫(yī)院檢驗(yàn)科;山東省東營(yíng)市東營(yíng)區(qū)人民醫(yī)院老年科;山東省東營(yíng)市東營(yíng)區(qū)人民醫(yī)院兒科;
【分類號(hào)】：R734.2

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 陳秀珍;華蟾素注射液治療晚期腫瘤300例[J];中國(guó)中醫(yī)藥信息雜志;2005年02期

2 邱炳力;董桂蘭;;華蟾素注射液治療晚期惡性腫瘤60例臨床分析[J];中國(guó)當(dāng)代醫(yī)藥;2010年32期

3 呂福鳴,孫清河,王慧娟,李新建;華蟾素注射液對(duì)豚鼠皮試刺激試驗(yàn)的影響[J];新鄉(xiāng)醫(yī)學(xué)院學(xué)報(bào);2002年05期

4 陳燕平,劉秀娟;華蟾素注射液配合化療治療晚期惡性腫瘤臨床觀察[J];實(shí)用中西醫(yī)結(jié)合臨床;2003年02期

5 鄧春美,蘭海濤,張明,楊蘭,白順艷,劉秀宏;大劑量華蟾素治療惡性腫瘤32例療效觀察[J];成都醫(yī)藥;2003年06期

6 陳U，

本文編號(hào)：2485631